KR101986272B1 - 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도 - Google Patents

삼환식 화합물, 이를 포함하는 조성물 및 그의 용도 Download PDF

Info

Publication number
KR101986272B1
KR101986272B1 KR1020147016247A KR20147016247A KR101986272B1 KR 101986272 B1 KR101986272 B1 KR 101986272B1 KR 1020147016247 A KR1020147016247 A KR 1020147016247A KR 20147016247 A KR20147016247 A KR 20147016247A KR 101986272 B1 KR101986272 B1 KR 101986272B1
Authority
KR
South Korea
Prior art keywords
delete delete
branched
straight
halogen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147016247A
Other languages
English (en)
Korean (ko)
Other versions
KR20140099492A (ko
Inventor
쉬무엘 벤-사쏜
아리에 다간
샤론 페레스
Original Assignee
이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. filed Critical 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디.
Publication of KR20140099492A publication Critical patent/KR20140099492A/ko
Application granted granted Critical
Publication of KR101986272B1 publication Critical patent/KR101986272B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
KR1020147016247A 2011-11-15 2012-11-15 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도 Active KR101986272B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161559964P 2011-11-15 2011-11-15
US61/559,964 2011-11-15
US201261603508P 2012-02-27 2012-02-27
US61/603,508 2012-02-27
PCT/IL2012/050461 WO2013072915A1 (en) 2011-11-15 2012-11-15 Tricyclic compounds, compositions comprising them and uses thereof

Publications (2)

Publication Number Publication Date
KR20140099492A KR20140099492A (ko) 2014-08-12
KR101986272B1 true KR101986272B1 (ko) 2019-06-05

Family

ID=48429067

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147016247A Active KR101986272B1 (ko) 2011-11-15 2012-11-15 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도

Country Status (25)

Country Link
US (1) US9447040B2 (cg-RX-API-DMAC7.html)
EP (1) EP2802320B1 (cg-RX-API-DMAC7.html)
JP (1) JP6087367B2 (cg-RX-API-DMAC7.html)
KR (1) KR101986272B1 (cg-RX-API-DMAC7.html)
CN (1) CN104010636B (cg-RX-API-DMAC7.html)
AU (1) AU2012338362B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014011641B1 (cg-RX-API-DMAC7.html)
CA (1) CA2855759C (cg-RX-API-DMAC7.html)
CL (1) CL2014001278A1 (cg-RX-API-DMAC7.html)
CO (1) CO7020909A2 (cg-RX-API-DMAC7.html)
DK (1) DK2802320T3 (cg-RX-API-DMAC7.html)
ES (1) ES2729713T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20190927T1 (cg-RX-API-DMAC7.html)
HU (1) HUE043827T2 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN03610A (cg-RX-API-DMAC7.html)
MX (1) MX347570B (cg-RX-API-DMAC7.html)
PE (1) PE20141940A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014501061B1 (cg-RX-API-DMAC7.html)
PL (1) PL2802320T3 (cg-RX-API-DMAC7.html)
PT (1) PT2802320T (cg-RX-API-DMAC7.html)
RU (1) RU2624446C9 (cg-RX-API-DMAC7.html)
SG (1) SG11201402258UA (cg-RX-API-DMAC7.html)
SI (1) SI2802320T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013072915A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201404065B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016020919A1 (en) 2014-08-07 2016-02-11 Raziel Therapeutics Ltd. Compositions comprising tricyclic compounds, and uses thereof
WO2016203468A1 (en) * 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
EP4031130A4 (en) * 2019-09-15 2023-10-11 Raziel Therapeutics Ltd. COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS
AU2021213469B2 (en) * 2020-01-28 2026-06-04 Raziel Therapeutics Ltd. Compositions for the treatment of angiolipoma
WO2022058792A1 (en) * 2020-09-16 2022-03-24 Raziel Therapeutics Ltd. Compositions for the treatment of fat related conditions and disorders
EP4213835A4 (en) * 2020-09-16 2024-10-02 Raziel Therapeutics Ltd. COMPOSITIONS AND METHODS FOR TREATING LIPID-RELATED DISORDERS
WO2022234337A2 (en) * 2021-05-06 2022-11-10 Raziel Therapeutics Ltd. Crystalline carbazole derivative
US20240335424A1 (en) * 2021-07-28 2024-10-10 Raziel Therapeutics Ltd. Compositions and methods for treating lipoma pain
CN115073374B (zh) * 2022-06-14 2023-10-27 五邑大学 一种α-葡萄糖苷酶抑制剂及其制备方法和应用
WO2024100533A1 (en) * 2022-11-07 2024-05-16 Raziel Therapeutics Ltd. Crystalline carbazole derivative and methods of making thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090317372A1 (en) 2008-06-20 2009-12-24 Zoltan Kiss Small molecules for the reduction of high blood glucose level

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2590125A (en) * 1952-03-25 Quaternary-ammonium alkyl
US2676966A (en) * 1951-04-04 1954-04-27 Searle & Co Quaternary salts of 9-carbazolealkylamines and 10-acridanalkylamines and methods forpreparing same
US2676971A (en) * 1951-04-21 1954-04-27 Searle & Co Quaternary ammonium derivatives of aminoalkylxanthenes and aminoalkylthiaxanthenes
FR1186832A (fr) 1956-08-03 1959-09-02 Etablissements Clin-Byla Composés hétérocycliques dérivés du pyrrol et des benzopyrrols et leur fabrication
GB832568A (en) 1956-08-03 1960-04-13 Clin Byla Ets Heterocyclic compounds and production thereof
US2930798A (en) * 1956-08-03 1960-03-29 Clin Byla Ets 3-alkanoyl 1-tertiary-amino-alkyl indol oximes and production thereof
GB866418A (en) * 1958-01-25 1961-04-26 Bayer Ag Phenoxazine derivatives
US3836587A (en) * 1969-11-17 1974-09-17 American Cyanamid Co Organo phosphonium salts
AR205331A1 (es) * 1972-07-24 1976-04-30 Hoffmann La Roche Procedimiento para la preparacion de carbazoles
FR2691459B1 (fr) * 1992-05-25 1995-06-09 Adir Nouveaux derives de la phenothiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH11504905A (ja) 1995-05-05 1999-05-11 ノボ ノルディスク アクティーゼルスカブ 新規複素環の化学
US6440961B1 (en) * 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
EP1094063A1 (en) 1999-10-18 2001-04-25 Applied Research Systems ARS Holding N.V. 9-(Piperazinylalkyl)carbazoles as Bax-modulators
GB9925880D0 (en) 1999-11-01 1999-12-29 British Tech Group Int B-Carboline derivatives
DE60218155D1 (de) 2001-03-28 2007-03-29 Lilly Co Eli Substituierte carbazole als inhibitoren von spla2
WO2003027084A1 (en) 2001-09-25 2003-04-03 Dr. Reddy's Laboratories Ltd. Improved process for the preparation of optically active phenoxazine derivatives as antidiabetic agents
US7428091B2 (en) * 2004-11-15 2008-09-23 Gentex Corporation Electrochromic compounds and associated media and devices
US20070213359A1 (en) 2005-12-30 2007-09-13 Acadia Pharmaceuticals Inc. Bicyclic-nitrogen compounds as modulators of ghrelin receptor and uses thereof
UA107652C2 (en) * 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
CA2748813C (en) * 2009-01-09 2018-07-10 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8362277B2 (en) * 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9095572B2 (en) * 2009-01-09 2015-08-04 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090317372A1 (en) 2008-06-20 2009-12-24 Zoltan Kiss Small molecules for the reduction of high blood glucose level

Also Published As

Publication number Publication date
IN2014CN03610A (cg-RX-API-DMAC7.html) 2015-10-09
PE20141940A1 (es) 2014-12-18
RU2014119711A (ru) 2015-12-27
HUE043827T2 (hu) 2019-09-30
SI2802320T1 (sl) 2019-08-30
PH12014501061B1 (en) 2018-12-12
CN104010636A (zh) 2014-08-27
HRP20190927T1 (hr) 2019-08-23
WO2013072915A1 (en) 2013-05-23
MX347570B (es) 2017-05-02
MX2014005765A (es) 2015-09-23
US20140329877A1 (en) 2014-11-06
AU2012338362B2 (en) 2017-05-18
PH12014501061A1 (en) 2014-06-23
EP2802320A1 (en) 2014-11-19
BR112014011641B1 (pt) 2020-10-27
EP2802320B1 (en) 2019-02-20
BR112014011641A2 (pt) 2017-05-02
JP2014533264A (ja) 2014-12-11
CO7020909A2 (es) 2014-08-11
US9447040B2 (en) 2016-09-20
AU2012338362A1 (en) 2014-05-29
CA2855759A1 (en) 2013-05-23
JP6087367B2 (ja) 2017-03-01
EP2802320A4 (en) 2015-08-12
CA2855759C (en) 2020-03-10
RU2624446C9 (ru) 2018-04-04
PT2802320T (pt) 2019-06-17
CL2014001278A1 (es) 2014-12-26
ZA201404065B (en) 2015-11-25
SG11201402258UA (en) 2014-06-27
DK2802320T3 (da) 2019-05-27
CN104010636B (zh) 2017-04-12
ES2729713T3 (es) 2019-11-05
PL2802320T3 (pl) 2019-09-30
KR20140099492A (ko) 2014-08-12
RU2624446C2 (ru) 2017-07-04

Similar Documents

Publication Publication Date Title
KR20140099492A (ko) 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도
EP3438099B1 (en) Vortioxetine pamoic acid salt and crystal form thereof
JP5596680B2 (ja) 経口抗がん製剤
EP3458448A1 (en) Methods of using fasn inhibitors
CN106432161A (zh) 一类3‑烃基‑5,6‑二氧取代苯酞化合物及其制备方法和用途
EP3134393B1 (en) Cyclohexenyl compounds, compositions comprising them and uses thereof
CN116496205B (zh) 一种卡瑞斯汀的盐及其用途
WO2016020919A1 (en) Compositions comprising tricyclic compounds, and uses thereof
BR112012013325B1 (pt) Composição farmacêutica e uso
US9102636B2 (en) Analgesic compounds, compositions, and uses thereof
CN114072381B (zh) 氨基硫醇类化合物作为脑神经或心脏保护剂的用途
CA2990747C (en) Phenyl amino pyrimidine compound or polymorph of salt thereof
JPH0269417A (ja) 精神分裂病治療用組成物
WO2025255488A2 (en) Xanomeline quercetin complexes and trospium salts
CN103288664A (zh) 一种新的bapta衍生物、其制备方法及其医药用途
EA051858B1 (ru) Фармацевтически приемлемые соли соединения и способы их получения
JPH05140094A (ja) 置換（アミノフエニル）ヘテロアリールエチルアミンのエナンチオマー
RU2021124673A (ru) Новые кристаллические формы сукцинатной соли диметиламида 7-циклопентил-2-(5-пиперазин-1-илпиридин-2-иламино)-7h-пирроло[2,3-d]пиримидин-6-карбоновой кислоты
TW201930309A (zh) Ask1抑制劑化合物及其用途
WO1992001468A1 (fr) Inhibiteur d'enzyme de conversion d'endoserine ou remede contre les contractions vasculaires
HK1227389A1 (en) Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof
HK1227410A1 (en) Polymorphic forms of a steroid-like compound and methods for the preparation and use thereof
KR20150005818A (ko) 신규한 테노포비어 디소프록실 오로테이트 및 이의 제조방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20220630

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 8